Lionel Karlin

5.0k total citations
45 papers, 444 citations indexed

About

Lionel Karlin is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Lionel Karlin has authored 45 papers receiving a total of 444 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Hematology, 21 papers in Molecular Biology and 21 papers in Oncology. Recurrent topics in Lionel Karlin's work include Multiple Myeloma Research and Treatments (33 papers), Protein Degradation and Inhibitors (14 papers) and Peptidase Inhibition and Analysis (11 papers). Lionel Karlin is often cited by papers focused on Multiple Myeloma Research and Treatments (33 papers), Protein Degradation and Inhibitors (14 papers) and Peptidase Inhibition and Analysis (11 papers). Lionel Karlin collaborates with scholars based in France, United States and Spain. Lionel Karlin's co-authors include Bertrand Coiffier, María‐Victoria Mateos, Michel Delforge, Philippe Moreau, Kwee Yong, Christoph Driessen, Cyrille Touzeau, Alain Flinois, Michèle Cavo and Marc S. Raab and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Kidney International.

In The Last Decade

Lionel Karlin

42 papers receiving 441 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lionel Karlin France	13	308	253	237	78	76	45	444
Yogesh Jethava United States	10	249 0.8×	151 0.6×	206 0.9×	38 0.5×	53 0.7×	50	423
Jose Estevam United States	11	627 2.0×	361 1.4×	566 2.4×	30 0.4×	82 1.1×	16	754
Giambattista Bertani Italy	8	302 1.0×	70 0.3×	188 0.8×	42 0.5×	103 1.4×	20	460
Noa Biran United States	12	322 1.0×	226 0.9×	256 1.1×	24 0.3×	35 0.5×	89	427
Kelly Godby United States	11	695 2.3×	435 1.7×	501 2.1×	44 0.6×	99 1.3×	52	789
Avinash Desai United States	8	295 1.0×	309 1.2×	260 1.1×	68 0.9×	37 0.5×	20	501
Claudia Crippa Italy	13	818 2.7×	516 2.0×	735 3.1×	43 0.6×	76 1.0×	50	981
Jayastu Senapati United States	10	311 1.0×	162 0.6×	107 0.5×	28 0.4×	117 1.5×	77	480
Thomas G Martin United States	10	369 1.2×	263 1.0×	318 1.3×	25 0.3×	36 0.5×	19	504
Kenneth C. Anderson United States	6	424 1.4×	247 1.0×	316 1.3×	26 0.3×	46 0.6×	9	528

Countries citing papers authored by Lionel Karlin

Since Specialization

Citations

This map shows the geographic impact of Lionel Karlin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lionel Karlin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lionel Karlin more than expected).

Fields of papers citing papers by Lionel Karlin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lionel Karlin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lionel Karlin. The network helps show where Lionel Karlin may publish in the future.

Co-authorship network of co-authors of Lionel Karlin

This figure shows the co-authorship network connecting the top 25 collaborators of Lionel Karlin. A scholar is included among the top collaborators of Lionel Karlin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lionel Karlin. Lionel Karlin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Talbot, Alexis, Cyrille Hulin, Aurore Perrot, et al.. (2025). Retreatment With Anti-CD38-Based Combinations in Multiple Myeloma in Real-Life: Results From the Emmy Cohort Study. Clinical Lymphoma Myeloma & Leukemia. 25(12). 863–872. 1 indexed citations

Perrot, Aurore, Cyrille Hulin, Jérôme Lambert, et al.. (2025). MRD-driven strategy following IsaKRD induction in transplant-eligible NDMM: Primary endpoints of the phase 3 MIDAS trial.. Journal of Clinical Oncology. 43(16_suppl). 7500–7500. 1 indexed citations

Touzeau, Cyrille, Aurore Perrot, Cyrille Hulin, et al.. (2024). Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma. Blood. 143(20). 2029–2036. 28 indexed citations

Hulin, Cyrille, Jérôme Lambert, Salomon Manier, et al.. (2024). Phase 3 randomized study of isatuximab (Isa) plus lenalidomide and dexamethasone (Rd) with bortezomib versus isard in patients with newly diagnosed transplant ineligible multiple myeloma (NDMM TI).. Journal of Clinical Oncology. 42(16_suppl). 7501–7501. 1 indexed citations

Ocio, Enrique M., Aurore Perrot, Pierre Bories, et al.. (2024). Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible or with No Immediate Intent for Transplant: Long-Term Efficacy and Safety in a Phase 1b Study. Blood. 144(Supplement 1). 1976–1976. 1 indexed citations

Manier, Salomon, Alexander M. Lesokhin, Mohamad Mohty, et al.. (2023). P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES. HemaSphere. 7(S3). e26808c7–e26808c7. 3 indexed citations

Usmani, Saad Z., Lionel Karlin, Lotfi Benboubker, et al.. (2023). MM-162 Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study. Clinical Lymphoma Myeloma & Leukemia. 23. S477–S477. 2 indexed citations

Ocio, Enrique M., Yvonne A. Efebera, Roman Hájek, et al.. (2023). ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study. Haematologica. 109(3). 867–876. 5 indexed citations

Ocio, Enrique M., Yvonne A. Efebera, Roman Hájek, et al.. (2020). ANCHOR (OP-104): Melflufen Plus Dexamethasone (dex) and Daratumumab (dara) or Bortezomib (BTZ) in Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and/or a Proteasome Inhibitor (PI) - Updated Efficacy and Safety. Blood. 136(Supplement 1). 9–10. 15 indexed citations

10.

Ocio, Enrique M., Yvonne A. Efebera, Miquel Granell, et al.. (2019). ANCHOR (OP-104): Updated Efficacy and Safety from a Phase 1/2 Study of Melflufen and Dexamethasone Plus Bortezomib or Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD or a Proteasome Inhibitor (PI). Blood. 134(Supplement_1). 3124–3124. 12 indexed citations

11.

Decaux, Olivier, Margaret Macro, Sophie Gourgou, et al.. (2019). Four-Year Interim Analysis of Miroir, a French Multicenter, Non-Interventional Study of Pomalidomide in Relapsed/Refractory Multiple Myeloma. Blood. 134(Supplement_1). 1836–1836.

12.

Quellec, Sandra Le, et al.. (2019). A Prolonged Treatment Response in Acquired Von Willebrand Syndrome. Hämostaseologie. 39(4). 409–412. 2 indexed citations

13.

Pour, Luděk, Miquel Granell, Roman Hájek, et al.. (2018). The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with Rrmm; First Report on Phase 1 Data. Blood. 132(Supplement 1). 1967–1967. 3 indexed citations

14.

Sens, Florence, et al.. (2017). Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study. American Journal of Nephrology. 46(5). 355–363. 8 indexed citations

15.

Raab, Marc S., Michèle Cavo, Michel Delforge, et al.. (2016). Multiple myeloma: practice patterns across Europe. British Journal of Haematology. 175(1). 66–76. 77 indexed citations

16.

Garderet, Laurent, Eric Beohou, Denis Caillot, et al.. (2016). Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study. Haematologica. 101(11). 1390–1397. 45 indexed citations

17.

Bonnet, Christophe, Thierry Lamy, Christophe Fruchart, et al.. (2016). Ibrutinib in Association with R-DHAP/Ox for Patients with Relapsed/Refractory B-Cell Lymphoma: Preliminary Results of the Biblos Phase Ib Lysa Study. Blood. 128(22). 5384–5384. 3 indexed citations

18.

Fouquet, Guillemette, Margaret Macro, O. Decaux, et al.. (2015). Le pomalidomide dans le myélome multiple. La Revue de Médecine Interne. 36(9). 613–618. 1 indexed citations

19.

Leleu, Xavier, Steven Le Gouill, Lionel Karlin, et al.. (2014). Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM). Blood. 124(21). 4478–4478. 3 indexed citations

20.

Karlin, Lionel, Stéphanie Harel, Enguerran Mouly, et al.. (2012). The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo. Haematologica. 97(7). 1101–1109. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact